NCT03807986 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Cho C, Cho E, Kim N, Shin J, Woo S, Lee J, Lee J, Lee E, Ha J
Biophysical properties of striae rubra and striae alba in human skin: Comparison with normal skin. Skin Res Technol. 2018 Oct 22. doi: 10.1111/srt.12645. [Epub ahead of print]
Forbat E, Al-Niaimi F
Treatment of striae distensae: An evidence-based approach. J Cosmet Laser Ther. 2018 Feb 16:1-9. doi: 10.1080/14764172.2017.1418515. [Epub ahead of print]
Hague A, Bayat A
Therapeutic targets in the management of striae distensae: A systematic review. J Am Acad Dermatol. 2017 Sep;77(3):559-568.e18. doi: 10.1016/j.jaad.2017.02.048. Epub 2017 May 24. Review.
Watson RE, Parry EJ, Humphries JD, Jones CJ, Polson DW, Kielty CM, Griffiths CE
Fibrillin microfibrils are reduced in skin exhibiting striae distensae. Br J Dermatol. 1998 Jun;138(6):931-7.

The Combination Therapy of Nanofat Grafting and Platelet-Rich Plasma Injection Compared With Microfat Grafting and Platelet-Rich Plasma Injection Synergy in Treating Striae Distensae

Details for clinical trial NCT03807986

Clinical trial NCT03807986 - References